Interleukin-1 receptor-associated kinase 4 is critical in the modulation of inflammatory responses through Toll-like receptor and IL-1R signaling.

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK ...

In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability ...

A recent study published in Progress in Neuropsychopharmacology & Biological Psychiatry suggests that cannabidiol (commonly ...

The MAVERIC-2 trial will evaluate the impact of CardiolRx™ in recurrent pericarditis patients following the cessation of ...

The Food and Drug Administration has granted Fast Track designation to GNSC-001 for the treatment of osteoarthritis of the knee.

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...

(TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug ...

BioSciences announced new data demonstrating its gene therapy for osteoarthritis candidate, PCRX-201, provided sustained ...

Inflammasome activation builds interleukin-1, which acts as a proinflammatory mediator and induces vasodilation, recruitment of additional leucocytes and the expression of proinflammatory cytokines ...

Cardiol Therapeutics Inc. shares N.CRDL are trading off 7 cents at $1.76.

Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...